Insulin Prices: Sen. Grassley Asks Sponsors For Details On PBM Rebates
Executive Summary
Letters to Lilly, Novo Nordisk and Sanofi signal potential next avenue for Finance Committee's investigation after CEO hearing on Tuesday.
You may also be interested in...
Express Scripts Insulin Program Lowers Cost Sharing With Supplemental Manufacturer Discounts
New wrinkle on lowering out-of-pocket spending differs from point-of-sale rebates and manufacturer copay assistance cards, the PBM says, and is not expected to increase plan costs.
Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.
Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.